Business Context and Reporting Period
This Form 8-K was filed by Xenetic Biosciences, Inc. on January 14, 2014. The report details a corporate name change and a reverse stock split approved by the board of directors and a majority of shareholders, as previously disclosed in the Form 10-Q filed on January 10, 2014.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate structural changes rather than financial performance.
Material Changes
- Corporate Name: Changed to "Xenetic Biosciences, Inc."
- Stock Split: A reverse split of common stock on a 1-for-10 basis.
- Trading Symbol: Effective January 14, 2014, the symbol is GAIFD for 20 business days, after which it will change to XBIO.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the implementation of the name change and stock split.
Investor Verification Checklist
- Confirm the effective date of the 1-for-10 reverse stock split (January 14, 2014).
- Verify the temporary trading symbol (GAIFD) and the permanent symbol (XBIO) on the over-the-counter market.
- Review the previously filed Form 10-Q (January 10, 2014) for detailed shareholder approval records and financial context.